Mini-hepcidin Peptides for Iron Overload Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for iron overload diseases such as hereditary hemochromatosis and iron-loading anemias are burdensome and often ineffective, with regular phlebotomy being the only option for hemochromatosis and iron chelation showing frequent side effects and limited efficacy.
Innovation Solution
Development of peptides that mimic hepcidin activity by binding to ferroportin, inducing its internalization and degradation, thereby regulating iron levels, including specific peptide structures and modifications that enhance activity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If regular phlebotomy is used to treat hereditary hemochromatosis, then iron overload is reduced, but the treatment is very burdensome for patients
Solution Approach 1:
The patent creates mini-hepcidin peptides (copies of the natural hepcidin hormone) that replicate its iron-regulatory function. These synthetic peptides bind to ferroportin and induce its internalization and degradation, thereby reducing iron overload without requiring repeated phlebotomy procedures. This copying approach provides a pharmacological alternative that is less burdensome while maintaining therapeutic effectiveness.
2Reliability
If iron chelation is used to treat iron-loading anemias, then iron overload is reduced, but the treatment is very burdensome, sometimes ineffective and accompanied by frequent side effects
Solution Approach 1:
The mini-hepcidin peptides replicate the natural hepcidin mechanism of action by binding to ferroportin and inducing its degradation. This approach mimics the body's natural iron regulation system rather than using external chelating agents, thereby achieving iron reduction without the side effects associated with iron chelation therapy.
Solution Approach 2:
The hepcidin peptide therapy leverages the body's own iron regulatory pathways. By administering hepcidin peptides that naturally bind to ferroportin and trigger its internalization, the treatment uses the body's inherent mechanisms to eliminate excess iron, avoiding the need for exogenous chelating substances that cause side effects.
3Length of moving object
If the N-terminal region of hepcidin is deleted to create shorter peptides, then peptide length is reduced, but iron-regulatory function is lost
Solution Approach 1:
The patent segments the full-length hepcidin peptide to identify the minimal functional unit required for iron regulation. Through systematic deletion studies, the invention determined that residues 3-10 (Hep3-10) constitute the essential N-terminal segment that retains bioactivity. This segmentation approach identifies the critical functional domain while removing non-essential portions.
Solution Approach 2:
The invention extracts the essential N-terminal segment (residues 3-10) from the full-length hepcidin peptide to create a mini-hepcidin that retains iron-regulatory function. This extracted segment contains the critical amino acids necessary for ferroportin binding and internalization, while eliminating the need for the complete 25-residue sequence.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively lower plasma iron concentrations, providing a potential therapeutic alternative to existing treatments by mimicking hepcidin activity, thus addressing the limitations of current treatments for iron overload diseases.
Implementation Method 1
Hepcidin acts by binding to its receptor, the iron export channel ferroportin, and causing its internalization and degradation
Data Source
Figure 1~2B
Figure 3A~3B
Figure 3C~4
AI summary
Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.